Etcamah camizestrant

FDA grants accelerated approval to Etcamah for ESR1-mutated advanced breast cancer

The ctDNA-guided approval allows an early treatment switch before imaging shows progression, while confirmatory evidence and important safety warnings remain.

Read More »